COMP <GO>
ENGN vs BDTX // FREE CASH FLOW YIELD
enGene Therapeutics Inc. (NASDAQ) VS. Black Diamond Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ENGN 0
— BDTX 4
■ METRIC PARITY
LAST: $1.53 (0.00%) • MKT CAP: $102.5M
fcf-yield
—
LAST: $1.78 (-4.30%) • MKT CAP: $106.9M
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENGN VS. BDTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENGN | BDTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 10.80% | -45.80 | BDTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 6.9x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 5/9 | -3.00 | BDTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.0 | 45.4 | -8.38 | BDTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $102.5M | $106.9M | -$4.3M | BDTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENGN REV | BDTX REV | ENGN GROSS % | BDTX GROSS % | ENGN FCF | BDTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$100.7M | $29.6M |
| FY 2024 | $0 | $0 | — | — | -$49.2M | -$62.3M |
| FY 2023 | $0 | $0 | — | — | -$24.7M | -$66.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENGN // BETA —
BDTX // BETA —